Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Siliq (brodalumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.
• This summary is based on the review of 17 systematic review(s)/meta-analysis(es). ^[1-17]
• Infliximab, bimekizumab, ixekizumab, risankizumab, and brodalumab demonstrated the highest effectiveness in achieving PASI 90, with risankizumab, brodalumab, and guselkumab among the most effective therapies. Brodalumab outperformed etanercept, ustekinumab, adalimumab, secukinumab, and guselkumab in PASI 90 outcomes.
• IL-17 and IL-23 inhibitors, particularly brodalumab, ixekizumab, and risankizumab, consistently showed higher response rates in PASI 75 and PASI 100 outcomes compared to other treatments.
• Ixekizumab was the most effective in achieving complete resolution of nail psoriasis, followed by brodalumab and adalimumab. Guselkumab and IL-17 inhibitors were effective in managing psoriatic arthritis, particularly in resolving enthesitis and dactylitis.
• No significant differences were found in the short-term efficacy of IL-17 inhibitors, including brodalumab, between Caucasian and Asian populations.
• Brodalumab frequently caused nasopharyngitis, upper respiratory tract infections, injection site reactions, headache, and diarrhea.
• No significant difference in SAE risk between brodalumab and placebo; methotrexate had a lower SAE risk than most biological treatments.
• Brodalumab had higher rates of adverse events than some biologics but was similar to ixekizumab, particularly in injection site reactions and nasopharyngitis.
• There is no population types or subgroups information available in the reviewed studies.